Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma Post author: Post published:March 17, 2026 Post category: Continue ReadingGenetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma Post author: Post published:March 17, 2026 Post category: Continue ReadingA Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma
Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol Post author: Post published:March 17, 2026 Post category: Continue ReadingNonconforming Lisocabtagene Maraleucel Expanded Access Protocol
Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin’s Lymphoma Post author: Post published:March 17, 2026 Post category: Continue ReadingStudy of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin’s Lymphoma
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma Post author: Post published:March 17, 2026 Post category: Continue ReadingA Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells Post author: Post published:March 17, 2026 Post category: Continue ReadingLong-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer Post author: Post published:March 17, 2026 Post category: Continue ReadingPSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer
A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia Post author: Post published:March 1, 2026 Post category: Continue ReadingA Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia
Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release Post author: Post published:March 1, 2026 Post category: Continue ReadingExpanded Access Program of AMTAGVI That is Out of Specification for Commercial Release
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation Post author: Post published:March 1, 2026 Post category: Continue ReadingA Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
